Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-TROP-2/MMAE antibody-drug conjugate LCB84

An antibody-drug conjugate (ADC) composed of Hu2G10, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1), conjugated via a beta-glucuronidase-cleavable linker to monomethyl auristatin E (MMAE), an auristatin derivative and a potent microtubule disrupting agent, with potential antineoplastic activity. Upon administration of anti-TROP-2/MMAE ADC LCB84, the anti-TROP-2 antibody targets and binds to TROP-2 expressed on tumor cells. Upon binding and internalization, MMAE is released upon cleavage by the cancer-associated lysosomal enzyme beta-glucuronidase. MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis. This induces cell death in TROP-2-expressing cancer cells. TROP-2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-TROP-2/MMAE ADC LCB84
Code name:LCB 84
LCB-84
LCB84
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search